Stay updated with breaking news from Professor Toby Maher. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
STOCKHOLM, SWEDEN / ACCESSWIRE / May 20, 2024 / Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis reflected an increase in...
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore" or the "Company"), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs),...
The new results show stabilization of disease already from week 6 and confirm the unprecedented increase in lung function over timeVicore will accelerate clinical developmentInvitation to conference
The AIR trial is a single arm, multicenter phase 2 study in patients with idiopathic pulmonary fibrosis (IPF)Interim data have shown stabilization of the disease and an increase in lung capacity
("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2...